Recombinant protein · developed by Protalix
Human Glucocerebrosidase is a recombinant form of the human lysosomal enzyme glucocerebrosidase, which breaks down glucosylceramide. It is studied in Gaucher Disease, a condition caused by deficient glucocerebrosidase activity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00258778 | Phase 1 | Gaucher Disease | Completed | PLX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gaucher Disease
See PLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PLX catalysts and pipeline →